Blood Cancer: Denosumab for Smoldering Multiple Myeloma
Research Question:
Is denosumab, delivered as an injection under the skin, safe and well-tolerated in
people with smoldering multiple myeloma? And can denosumab reduce the risk of getting
multiple myeloma?
Basic Study Information
Purpose:
This is a trial of denosumab 120mg subcutaneous (under the skin) for patients with
smoldering multiple myeloma (SMM). SMM is a plasma cell disorder has a high risk of
progressing to multiple myeloma (MM).
Participants will be recruited from the James P. Wilmot Cancer Center, University
of Rochester in Rochester, New York. Patients seen in the inpatient or outpatient
setting with histologically confirmed SMM will be evaluated for this study.
20 patients will be treated with a dose of denosumab every 4 weeks over the course
of a year. Patients will be followed after completion of the study for an additional
2 years. All patients will take daily vitamin D and calcium supplements.
Location: University of Rochester Medical Center
Study Reference #: UMMY18121
Lead Researcher (Principal Investigator)
Lead Researcher: Brea Lipe
Study Contact Information
Study Coordinator: Kaitlyn Burrows
Phone: (585) 275-5150
Email: Kaitlyn_Burrows@URMC.Rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search